Genome Valley

Thought Leaders

Opportunity Next.

Gear up to interact with the game changers. Hear, observe, learn and connect with the best of Industry Leaders and policy Influencers. BioAsia 2013 brings you the best of best under one roof on the 28th, 29th and 30th of January, 2013.

Be There.

Dr. Rajeev Soni
Associate Vice President R&D,
Biocon Ltd.

Rajeev Soni is a Ph.D. in Molecular Biology and Biotechnology from the University of Cambridge, U.K. and has over 20 years of research and development experience including industry and academia. He has been responsible for the design and management of state of the art molecular biology labs at Lidak (Avanir) Pharmaceuticals, La Jolla, USA, De Montfort University, Leicester, U.K., The Naval Research Lab, Washington D.C., USA, Ranbaxy biotechnology, Gurgaon, India and at PREMAS, Gurgaon, India. He has managed mutli-skilled and mutli-lingual teams across various functions and countries.

In 2005, he founded Premas Biotech, along with a team of entepreneurs and investors and served as President and COO from inception till Jan. 2012. He was responsible for in-house and contract research and development. He managed marketing and business development aspects of the business as well and has keen understanding of the life science market in India, Europe and USA. He is currently serving as Associate Vice President R&D at Biocon Ltd.

He was part of the implementation team for "Lean Management" or the "Toyota production Process" at PREMAS; possibly, one of the first companies in India to implement this in the biology sector coupled with electronic lab-notebook and SDMS for a 21CFR part 11 compliant set up. He has successfully delivered over 150 proteins in 4 years while at PREMAS from mg to gm levels. His area of specialization is varied and includes Innovative drug discovery research for Cancer and Infectious diseases focusing on both NCE's and Bio-therapeutics, CRAMS (contract research and manufacturing services), enzyme engineering for biofuels, development and refinement of systems for protein expression in E.coli, yeast and mammalian cells, fund raising, strategic planning, consulting for biosimilar and novel bio-therapeutics and business development in the biotech sector.

To Connect and Network with Freda C. Lewis-Hall Click Here